Form 4: CalciMedica Chief Scientific Officer Granted Stock Options Following Shareholder Approval
Executive Stock Option Grant
CalciMedica, Inc. has reported that its Chief Scientific Officer, Kenneth A. Stauderman, was granted 47,125 employee stock options with an exercise price of $1.53, following stockholder approval of an amended equity incentive plan.
Summary
- Kenneth A. Stauderman, Chief Scientific Officer of CalciMedica, Inc. (CALC), was granted 47,125 employee stock options.
- The options have an exercise price of $1.53 per share.
- The grant was approved by the Board of Directors on April 23, 2025, contingent on stockholder approval of the Company's 2023 Equity Incentive Plan amendment.
- Stockholders approved the Amended 2023 Equity Incentive Plan on June 24, 2025.
- The options are immediately exercisable and expire on April 22, 2035.
- Following this transaction, Kenneth A. Stauderman beneficially owns 47,125 derivative securities directly.
Sentiment
Score: 6
Explanation: The sentiment is slightly positive as the grant of stock options to a key executive serves to align their interests with shareholders and incentivize performance, which is generally viewed favorably. It is a routine compensation event.
Positives
- The grant of stock options to the Chief Scientific Officer aligns executive incentives with shareholder interests, potentially encouraging long-term performance and retention.
- The option grant was part of an approved equity incentive plan, demonstrating structured executive compensation.
Future Outlook
The document does not contain any explicit forward-looking statements or guidance beyond the terms of the option grant itself.
Management Comments
- The option grant was approved by the Board of Directors of CalciMedica, Inc. on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan.
Industry Context
The granting of stock options to key executives is a standard practice in the biotechnology and pharmaceutical industries, used to attract, retain, and incentivize talent by aligning their financial interests with the long-term performance of the company.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Plan Amendment Approval | Stockholders approved an amendment to the Company's 2023 Equity Incentive Plan (Amended 2023 EIP) on June 24, 2025, under which the stock option was granted. | 06/24/2025 | This approval enables the company to continue using equity-based compensation to incentivize employees and executives, aligning their interests with long-term company performance and shareholder value. |
Stakeholder Impact
- Shareholders: Potential for minor dilution from the exercise of options, but also benefit from incentivized executive performance.
- Employees: The grant is part of a broader equity incentive plan, which can positively impact employee morale and retention by offering similar compensation opportunities.
Key Dates
| Date | Description |
|---|---|
| 04/23/2025 | Board of Directors approved the option grant, subject to stockholder approval of the Amended 2023 Equity Incentive Plan. |
| 06/24/2025 | Stockholders approved the Amended 2023 Equity Incentive Plan, under which the option was granted. This is also listed as the earliest transaction date. |
| 06/26/2025 | Date the Form 4 filing was signed and submitted. |
| 04/22/2035 | Expiration date of the employee stock options. |
Keywords
CalciMedica, CALC, Stock Option, Executive Compensation, Form 4, Equity Incentive Plan, Insider Transaction, Chief Scientific Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.